Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GOVX B11

Drug Profile

GOVX B11

Alternative Names: DNA/MVA; DNA/MVA-unadjuvanted-vaccine; GEO-D02 DNA vaccine; GEO-D03 DNA vaccine; GeoVax Clade B DNA/MVA HIV/AIDS Vaccine; GeoVax-Clade-B-DNA/MVA-HIV/AIDS-unadjuvanted-vaccine; GOVX B01; pGA2-JS7 + MVA/HIV62

Latest Information Update: 08 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GeoVax Labs; National Institute of Allergy and Infectious Diseases
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 24 Oct 2019 National Institute of Allergy and Infectious Diseases withdraws a phase I trial for HIV infections prior to enrolment as the protocol is undergoing additional revisions (IM) (NCT04041674)
  • 22 Aug 2019 GeoVax Labs, Duke University, University of Washington, University of Maryland and National Institute of Allergy and Infectious Diseases plan a phase I trial for HIV infections (Prevention) (IM, Injection), in September 2020 (NCT04041674)
  • 15 Mar 2018 Phase I development is ongoing for HIV infections (GeoVax website, March 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top